Evidence map›Paper›PMID 36616944›Full record

ArticleSensors (Basel, Switzerland)2022

Nanoscale Investigation of DNA Demethylation in Leukemia Cells by Means of Ultrasensitive Vibrational Spectroscopy.

Anca Onaciu, Valentin Toma, Cristian Moldovan, Adrian Bogdan Țigu, Diana Cenariu, Carina Culic, Rareș Mario Borșa, Luca David, Gabriela Fabiola Știufiuc, Romulus Tetean and 2 more

Open access · goldAbstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Anca OnaciuMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
Valentin TomaMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.ORCID 0000-0001-8322-1180
Cristian MoldovanMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
Adrian Bogdan ȚiguMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.ORCID 0000-0001-9397-0791
Diana CenariuMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
Carina CulicDepartment of Odontology, Endodontics, Oral Pathology, Faculty of Dental Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400001 Cluj-Napoca, Romania.
Rareș Mario BorșaFaculty of Dental Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
Luca DavidFaculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.
Gabriela Fabiola ȘtiufiucFaculty of Physics, "Babes-Bolyai" University, 400084 Cluj-Napoca, Romania.
Romulus TeteanFaculty of Physics, "Babes-Bolyai" University, 400084 Cluj-Napoca, Romania.
Ciprian TomuleasaMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.ORCID 0000-0001-5500-1519
Rareș Ionuț ȘtiufiucMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.ORCID 0000-0001-6769-1545
Iuliu Hațieganu University of Medicine and Pharmacy · ROBabeș-Bolyai University · RO

Funding

Iuliu Hațieganu University of Medicine and Pharmacy 35/172/ 17.12.2021Iuliu Hațieganu University of Medicine and Pharmacy 35/194/17.12.2021
6 · The paper itself

Abstract

DNA methylation is a crucial epigenetic hallmark of cancer development but the experimental methods able to prove nanoscale modifications are very scarce. Over time, Raman and its counterpart, surface-enhanced Raman scattering (SERS), became one of the most promising techniques capable to investigate nanoscale modifications of DNA bases. In our study, we employed Raman/SERS to highlight the differences between normal and leukemia DNA samples and to evaluate the effects of a 5-azacytidine treatment on leukemia cells. To obtain spectral information related to DNA base modifications, a DNA incubation step of 4 min at 94 °C, similar to the one performed in the case of RT-PCR experiments, was conducted prior to any measurements. In this way, reproducible Raman/SERS spectra were collected for all genomic DNA samples. Our Raman results allowed discrimination between normal and cancer DNAs based on their different aggregation behavior induced by the distinct methylation landscape present in the DNA samples. On the other hand, the SERS spectra collected on the same DNA samples show a very intense vibrational band located at 1008 cm

Indexed as

LeukemiaVibrationDNADNA DemethylationHumansSpectrum Analysis, RamanDNA5-azacytidineDNA demethylationleukemiaRaman spectroscopySERS

Identifiers

PMID36616944
PMCPMC9823440
OpenAlexW4313238139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.